CIK 0001869105 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
BridgeBio Oncology Therapeutics, Inc.
Sign in to watch- Ticker
- BBOT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857 702 0377
- Business address
- 256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Helix Acquisition Corp. II
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-16 | Chen Bihua Director | Grant or award · Stock Option (Right to Buy) | +31,675 | 31,675 | ||
| 2026-06-16 | Bauer Jake Director | Grant or award · Stock Option (Right to Buy) | +31,675 | 31,675 | ||
| 2026-06-16 | Kumar Neil Director | Grant or award · Stock Option (Right to Buy) | +31,675 | 31,675 | ||
| 2026-05-10 | Elmelech Idan COO & Principal Financial Ofcr | Grant or award · Stock Option (Right to Buy) | +758,222 | 758,222 | ||
| 2026-05-10 | Beltran Pedro President and CEO | Grant or award · Stock Option (Right to Buy) | +1,103,837 | 1,103,837 | ||
| 2026-04-01 | Ben Yong Chief Med & Dev Officer | Shares withheld for taxes | −1,047 | $9.03 | $9K | 45,623 |
| 2026-04-01 | Beltran Pedro President and CEO | Shares withheld for taxes | −1,047 | $9.03 | $9K | 45,623 |
| 2026-04-01 | Mehra Uneek Former Officer | Shares withheld for taxes | −524 | $9.03 | $5K | 22,806 |
| 2026-03-24 | Lebowitz Peter F Director | Grant or award · Stock Option (Right to Buy) | +63,350 | 63,350 | ||
| 2026-03-10 | Mehra Uneek Chief Financial Officer | Grant or award | +23,330 | 23,330 | ||
| 2026-03-10 | Mehra Uneek Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +105,000 | 105,000 | ||
| 2026-03-10 | Beltran Pedro Chief Scientific Officer | Grant or award | +46,670 | 46,670 | ||
| 2026-03-10 | Beltran Pedro Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +210,000 | 210,000 | ||
| 2026-03-10 | Ben Yong Chief Med & Dev Officer | Grant or award | +46,670 | 46,670 | ||
| 2026-03-10 | Ben Yong Chief Med & Dev Officer | Grant or award · Stock Option (Right to Buy) | +210,000 | 210,000 | ||
| 2026-01-01 | Wallace Eli M. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +1,114,400 | 1,114,400 | ||
| 2025-12-10 | Wallace Eli M. Chief Executive Officer | Returned to the company · Stock Option (Right to Buy) | −1,114,400 | 500,000 | ||
| 2025-10-10 | BridgeBio Pharma LLC 10% owner | Other acquisition | +784,720 | 14,589,846 | ||
| 2025-10-02 | Wallace Eli M. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +1,614,400 | 1,614,400 | ||
| 2025-08-26 | Tipirneni Praveen P. Director | Grant or award · Stock Option (Right to Buy) | +52,269 | 52,269 |
Page 2 of 4 · 69 trades